SG11201903232UA - Process for the preparation of (3s,4s)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3h-imidazo[4,5-c]pyridine-5(4h)-carboxylate - Google Patents
Process for the preparation of (3s,4s)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3h-imidazo[4,5-c]pyridine-5(4h)-carboxylateInfo
- Publication number
- SG11201903232UA SG11201903232UA SG11201903232UA SG11201903232UA SG11201903232UA SG 11201903232U A SG11201903232U A SG 11201903232UA SG 11201903232U A SG11201903232U A SG 11201903232UA SG 11201903232U A SG11201903232U A SG 11201903232UA SG 11201903232U A SG11201903232U A SG 11201903232UA
- Authority
- SG
- Singapore
- Prior art keywords
- building
- cambridgeshire
- proximagen
- minerva
- limited
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111H1111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/078363 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every C07D 471/04 (2006.01) C07C 309/04 (2006.01) kind of regional protection available): ARIPO (BW, GH, C07C 5 9 / 5 0 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (21) International Application Number: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, PCT/GB2017/053218 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (22) International Filing Date: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 25 October 2017 (25.10.2017) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English (26) Publication Language: English Published: (30) Priority Data: — with international search report (Art. 21(3)) 1618029.1 25 October 2016 (25.10.2016) GB (71) Applicant: PROXIMAGEN LIMITED [GB/GB]; Miner- va Building 250, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). (72) Inventors: HORGAN, Anne; c/o Proximagen Limited, Minerva Building 250, Babraham Research Campus, Cam- bridge Cambridgeshire CB22 3AT (GB). HAGLUND, Olof; c/o Proximagen Limited, Minerva Building 250, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). PATIENT, Lee; c/o Proximagen Lim- ited, Minerva Building 250, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). SAVORY, Edward; c/o Proximagen Limited, Minerva Building 250, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). HIGGINBOTTOM, Michael; c/o Prox- imagen Limited, Minerva Building 250, Babraham Re- search Campus, Cambridge Cambridgeshire CB22 3AT (GB). ASHWOOD, Michael; c/o Proximagen Limited, Minerva Building 250, Babraham Research Campus, Cam- bridge Cambridgeshire CB22 3AT (GB). Agent: GILL JENNINGS & EVERY LLP; The (74) Broadgate Tower, 20 Primrose Street, London EC2A 2ES (GB). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) 1-1 M SO M GC IN ......_ © (54) Title: PROCESS FOR THE PREPARATION OF (3S,4S)-TETRAHYDROFURAN-3-YL 4-ISOPROPYL-6,7-DIHYDRO-3H- GO\" IMIDAZO[4,5-C]PYRIDINE-5(4H)-CARBOXYLATE 1-1 0 (57) : The invention relates to an improved process for the synthesis of (3S,4S)-tetrahydrofuran-3-y14-isopropy1-6,7-dihydro-3 \" H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1618029.1A GB201618029D0 (en) | 2016-10-25 | 2016-10-25 | New process |
| PCT/GB2017/053218 WO2018078363A1 (en) | 2016-10-25 | 2017-10-25 | Process for the preparation of (3s,4s)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3h-imidazo[4,5-c]pyridine-5(4h)-carboxylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903232UA true SG11201903232UA (en) | 2019-05-30 |
Family
ID=57738076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903232UA SG11201903232UA (en) | 2016-10-25 | 2017-10-25 | Process for the preparation of (3s,4s)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3h-imidazo[4,5-c]pyridine-5(4h)-carboxylate |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10988473B2 (en) |
| EP (1) | EP3532472A1 (en) |
| JP (1) | JP2019532111A (en) |
| KR (1) | KR20190111895A (en) |
| CN (1) | CN110167932A (en) |
| AR (1) | AR109883A1 (en) |
| AU (1) | AU2017349458A1 (en) |
| BR (1) | BR112019008235A2 (en) |
| CA (1) | CA3040616A1 (en) |
| EA (1) | EA201991042A1 (en) |
| GB (1) | GB201618029D0 (en) |
| IL (1) | IL265985A (en) |
| MX (1) | MX2019004732A (en) |
| SG (1) | SG11201903232UA (en) |
| TW (1) | TW201815790A (en) |
| WO (1) | WO2018078363A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7614577A (en) * | 1976-01-07 | 1977-07-11 | Farmaceutici Italia | PROCESS FOR PREPARING NEW 4,5,6,7-TETRAHYDROIMIDAZO (4,5-C) -PYRIDINE DERIVATIVES. |
| PT2334672E (en) * | 2008-09-16 | 2014-01-02 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of ssao |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| GB201507036D0 (en) | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| CN104860993B (en) * | 2015-05-22 | 2017-08-22 | 北京盛诺基医药科技有限公司 | A kind of chromocor compound prodrug and application thereof |
| GB201513115D0 (en) * | 2015-07-24 | 2015-09-09 | Proximagen Ltd | New therapeutic compound and use in therapy |
| EP3386494A1 (en) | 2015-12-07 | 2018-10-17 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
-
2016
- 2016-10-25 GB GBGB1618029.1A patent/GB201618029D0/en not_active Ceased
-
2017
- 2017-10-24 TW TW106136527A patent/TW201815790A/en unknown
- 2017-10-25 BR BR112019008235A patent/BR112019008235A2/en not_active Application Discontinuation
- 2017-10-25 US US16/344,608 patent/US10988473B2/en active Active
- 2017-10-25 CA CA3040616A patent/CA3040616A1/en not_active Abandoned
- 2017-10-25 AR ARP170102966A patent/AR109883A1/en unknown
- 2017-10-25 CN CN201780065650.6A patent/CN110167932A/en active Pending
- 2017-10-25 JP JP2019542812A patent/JP2019532111A/en not_active Withdrawn
- 2017-10-25 WO PCT/GB2017/053218 patent/WO2018078363A1/en unknown
- 2017-10-25 EA EA201991042A patent/EA201991042A1/en unknown
- 2017-10-25 SG SG11201903232UA patent/SG11201903232UA/en unknown
- 2017-10-25 KR KR1020197015067A patent/KR20190111895A/en unknown
- 2017-10-25 EP EP17792146.7A patent/EP3532472A1/en not_active Withdrawn
- 2017-10-25 AU AU2017349458A patent/AU2017349458A1/en not_active Abandoned
- 2017-10-25 MX MX2019004732A patent/MX2019004732A/en unknown
-
2019
- 2019-04-11 IL IL265985A patent/IL265985A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019008235A2 (en) | 2019-07-16 |
| MX2019004732A (en) | 2019-10-07 |
| US10988473B2 (en) | 2021-04-27 |
| EA201991042A1 (en) | 2019-11-29 |
| CN110167932A (en) | 2019-08-23 |
| EP3532472A1 (en) | 2019-09-04 |
| AU2017349458A1 (en) | 2019-05-02 |
| TW201815790A (en) | 2018-05-01 |
| CA3040616A1 (en) | 2018-05-03 |
| US20200062746A1 (en) | 2020-02-27 |
| WO2018078363A1 (en) | 2018-05-03 |
| KR20190111895A (en) | 2019-10-02 |
| JP2019532111A (en) | 2019-11-07 |
| GB201618029D0 (en) | 2016-12-07 |
| IL265985A (en) | 2019-06-30 |
| AR109883A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201811719RA (en) | Conjugates for targeted cell surface editing | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201903091VA (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201406548WA (en) | Anti-malarial agents | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies |